Anwar Padhani

Here are updated infographics for comparing MRI and Systematic biopsy in biopsy naive men. PRECISION 🏹4M 🤼‍♂️MRI-First ⛹️‍♂️ and @cochranecollab 🥇@JelleBarentsz @radiolobt @mrsprostate @LondonProstate1 @ProstateUKProfs

🏅 #ACAR2026 Day 2 | #ESUR Honorary Lecture “Opportunities for Next Generation Imaging for Advanced #ProstateCancer” by professor @ProfPadhani 📌 A MUST-attend update for #GU/#oncology imagers. #GUImaging

Because you wouldn’t let it slide… these are rolling out today for our most requested feature: Prompt-Based Revisions: Tweak, tailor, and tune your slides just by prompting the revisions you want PPTX Support: You can now export your Slide Decks (Google Slides coming next!)

I scraped every single NotebookLM prompt that blew up on X, Reddit, and academic corners of the internet. Turns out most people are using NotebookLM like a fancy note-taker. That's insane. It's a full-blown research assistant that can compress 10 hours of analysis into 20 seconds if you feed it the right instructions. Here's what actually works:

Use decision curve analysis to evaluate models and markers!

🚨 New ESMO guideline on localized & locoregional prostate cancer! annalsofoncology.org/article/S0923-… 💥 Clear algorithms for diagnosis, risk stratification & treatment 🎯 Active surveillance where appropriate & escalation when needed 🤝 Multidisciplinary (evidence-based) globally aligned Good oncology isn’t about doing more…it’s about doing it right!! Congrats to @AttardLab @Ecastromarcos @stefanofanti4 @Silke_Gillessen @Prof_Nick_James @piet_ost @MarkARubin1 @ChrisSweens1 @Tilki_De @ZilliThomas @alison_tree and all the team! 👏🏼 @OncoAlert #OncoAlertAF @OncoReporte @myESMO @_SEOM

🚨 Special ACORE Expert Webinar 🚨 We are honored to host Prof. Anwar Padhani, one of the world’s foremost authorities in oncologic MRI. Join us for a high-impact, must-attend session on: Whole-body MRI in opportunistic cancer diagnosis: Dos and Don’ts A rare opportunity to learn directly from a global leader shaping modern cancer imaging. 📅 Thursday, January 29 | ⏰ 12:00 PM CST 🎓 This is not just a webinar — it’s a masterclass. Register here: [tinyurl.com/2ya6wt9z] #ACORE #Radiology #MRI #WholeBodyMRI #CancerImaging #OncologicImaging #RadiologyEducation #RadEdu #MedTwitter #ImagingExperts

Thrilled beyond words to share that I've been informed of my promotion to Professor of Radiology! Endless gratitude to my leadership, mentors, colleagues, residents/students, family, and patients most of all. Also, huge congratulations to amazing friends @sportsraddoc, @AmitGupta_83, and Yong Chen on their well-deserved promotions. Onward! 🚀 @UHRadiology @UH_RadiCLE @UH_RE_Institute

Just out in @TheLancet: an overview on current approaches to diagnosis and management of prostate cancer. sciencedirect.com/science/articl…

The UK National Screening Committee has decided there isn't enough evidence to recommend screening for the vast majority of men. But it's not the end. Our Director of Research, Dr Matthew Hobbs, explains more ⤵️ #ProstateCancer l #MensHealth l #Screening

Today’s UK National Screening Committee decision is profoundly concerning. Black men and men with a family history still won’t be offered screening, despite facing some of the highest risks and worst outcomes. This isn’t good enough. All high-risk men deserve access to screening. Sign our petition today: act.prostate-cancer-research.org.uk/a/say-yes-to-s…

Right decision? @IP_London @gucast @JelleBarentsz

Part 2: AI-targeted review AI flags all suspicious lesions on MRI. Radiologists verify each region and double-check negatives. This boosts detection, streamlines reporting, and reduces variability. Full paper: lnkd.in/diWn-bMU @ProfPadhani

ESUR: Opportunities for PSMA-PET/CT and whole-body MRI in advanced #ProstateCancer link.springer.com/article/10.100… This paper discusses the emerging role of PSMA-PET/CT and whole-body MRI (WB-MRI) in prostate cancer, emphasizing their superior accuracy over conventional CT and bone scans for detecting metastatic disease. These imaging modalities not only enhance metastasis detection and staging but also support disease characterization, biopsy targeting, treatment planning, response assessment, and theranostic strategies. While their potential to improve personalized management is clear, the authors stress that prospective clinical trials are needed to determine whether their use translates into meaningful improvements in survival or quality of life, highlighting key research questions for the field. @swoo_rad @lrusso_md @AilinRadio @IvoSchootsNL @Dr_A_Lakhani Tobias Penzkofer @ChariteBerlin @Mart_Pecoraro @Silke_Gillessen @RaqPerezLopez @ProfPadhani @OncoAlert 🚨 @AOmlin @nataliagandur

Want to know how men in the UK are being diagnosed and treated for prostate cancer? Latest national data out here 👇 Headlines- big upswing in diagnoses year on year, not all men getting maximal treatment and inequalities by ethnicity and deprivation

New prospective study: Pi™ delivers speed in real-world care ✅ 96% agreement between radiologists & Pi™ score ≥ 4.5 on biopsy decisions ⏱️ Avg 11-day faster biopsy for csPCa ⚖️ Threshold tweak captures ~75% csPCa, slight rise in false positives healthinnovationsouthwest.com/wp-content/upl…

Magnetic Resonance Imaging–based Biopsy Strategies in Prostate Cancer Screening: A Systematic Review sciencedirect.com/science/articl… Systematic review evaluated the benefit–harm balance of incorporating magnetic resonance imaging (MRI) into #ProstateCancer (PCa) screening as either a first-line test or a second-stage test after PSA >3 ng/ml. Across five first-line and four second-stage studies, MRI strategies were compared for cancer detection, biopsy avoidance, and histological outcomes. First-line MRI identified roughly twice as many clinically significant (GG ≥2) cancers as second-stage MRI but left a higher proportion of men MRI-negative, while second-stage MRI markedly reduced biopsy rates and increased the detection ratio of GG ≥2 versus GG 1 cancers with both targeted and systematic biopsies. Both approaches achieved positive benefit-to-harm ratios (>1), indicating net clinical benefit, though first-line MRI needs further feasibility evaluation and standardisation of MRI interpretation and biopsy protocols is essential for consistent screening quality. @IvoSchootsNL @LondonProstate1 @albers_pa @AsbachP @roodvdb @TobiasNordstrom @ShonitP @ProfPadhani @OncoAlert 🚨 @Silke_Gillessen @AOmlin @nataliagandur @bavilima

On this day in 1971, the first clinical CT scan was done on a prototype scanner at Atkinson Morley Hospital in London. Sir Godfrey Hounsfield and Dr. Allan M. Cormack co-invented the scanner to collect cross-sectional images of a patient, though the work was a culmination of many peoples' genius and dedication to radiology. Hounsfield and Cormack would both later win the Nobel Prize for their work. Happy 54th birthday to CT 🎉 And a big thank-you to everyone who makes computed tomography as great as it is. Photo 1: the first CT scanner, circa 1971 (image credit Science Museum Group) Photos 2-3: the same scanner on display at London's Science Museum

Missing something? Quality... expert readers.. 3T... any thing else...

Providing MRI quality is good, this is a no-brainer for the primary diagnostic setting. Here’s what internationally renowned experts think of the findings and why practice should change NOW 4/4: